Sanofi (SNY) US Services’ rilzabrutinib was granted FDA orphan designation status as a treatment of sickle cell disease, according to a post to the agency’s website.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi to invest at least $20B in U.S. through 2030
- U.S. biotech companies debate relocating trials outside U.S., Reuters reports
- Trump’s drug-price crackdown may lead to minor concessions, WSJ reports
- JPMorgan sees ‘most favored nation’ drug order facing ‘significant push back’
- White House publishes Trump executive order aimed at lowering drug prices